Publication:
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.

Simple item page
dc.contributor.authorCoelho, Teresa
dc.contributor.authorDispenzieri, Angela
dc.contributor.authorGrogan, Martha
dc.contributor.authorConceição, Isabel
dc.contributor.authorWaddington-Cruz, Márcia
dc.contributor.authorKristen, Arnt V
dc.contributor.authorWixner, Jonas
dc.contributor.authorDiemberger, Igor
dc.contributor.authorGonzalez-Moreno, Juan
dc.contributor.authorMaurer, Mathew S
dc.contributor.authorPlanté-Bordeneuve, Violaine
dc.contributor.authorGarcia-Pavia, Pablo
dc.contributor.authorTournev, Ivailo
dc.contributor.authorGonzalez-Costello, Jose
dc.contributor.authorCariou, Eve
dc.contributor.authorGonzález-Duarte, Alejandra
dc.contributor.authorGlass, Oliver
dc.contributor.authorChapman, Doug
dc.contributor.authorAmass, Leslie
dc.contributor.funderPfizeres_ES
dc.date.accessioned2023-09-05T08:56:07Z
dc.date.available2023-09-05T08:56:07Z
dc.date.issued2023-07-17
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThe THAOS registry and this analysis were sponsored by Pfizer. We thank all THAOS patients and investigators for their important contributions to this study. We also thank Pritam Gupta for statistical support on the manuscript. Medical writing support was provided by Emily Balevich, PhD, of Engage Scientific Solutions and was funded by Pfizer.es_ES
dc.format.page1es_ES
dc.identifier.citationAmyloid. 2023 Jul 17;1-4.es_ES
dc.identifier.doi10.1080/13506129.2023.2229484es_ES
dc.identifier.e-issn1744-2818es_ES
dc.identifier.journalAmyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosises_ES
dc.identifier.pubmedID37459334es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16408
dc.language.isoenges_ES
dc.publisherPearl Riveres_ES
dc.relation.publisherversion10.1080/13506129.2023.2229484es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Miocardiopatías Hereditariases_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titlePatients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.es_ES
dc.typeletter to the editores_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication52ada1ee-7241-4738-b46d-90a5ccc14894
relation.isAuthorOfPublication.latestForDiscovery52ada1ee-7241-4738-b46d-90a5ccc14894

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Patients with transthyretin amyloidosis_Amyloid_2023.pdf
Size:
903.26 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Grupos de investigación